Ultragenyx Pharmaceutical Inc.
US ˙ NasdaqGS ˙ US90400D1081

SecurityRARE / Ultragenyx Pharmaceutical Inc.
InstitutionParallel Advisors, LLC
Latest Disclosed Ownership185 shares
Latest Disclosed Value $ 4,255
Parallel Advisors, LLC reports 20.13% increase in ownership of RARE / Ultragenyx Pharmaceutical Inc.

On February 11, 2026 - Parallel Advisors, LLC filed a 13F-HR form disclosing ownership of 185 shares of Ultragenyx Pharmaceutical Inc. (US:RARE) valued at $4,255 USD as of December 31, 2025. The entity filed a previous 13F-HR on November 13, 2025 disclosing 154 shares of Ultragenyx Pharmaceutical Inc.. This represents a change in shares of 20.13% during the quarter. The current value of the position is $4,146 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-02-11 2025-12-31 13F ULTRAGENYX PHARMACEUTICAL INC COM Stock 90400D108 185 31 20.13 4 0.00 0.0001
2025-11-13 2025-09-30 13F ULTRAGENYX PHARMACEUTICAL INC COM Stock 90400D108 154 -578 -78.96 5 -84.62 0.0001
2025-07-08 2025-06-30 13F ULTRAGENYX PHARMACEUTICAL INC COM Stock 90400D108 732 669 1,061.90 27 1,200.00 0.0005
2025-04-08 2025-03-31 13F ULTRAGENYX PHARMACEUTICAL INC COM Stock 90400D108 63 -162 -72.00 2 -77.78 0.0001
2025-02-10 2024-12-31 13F ULTRAGENYX PHARMACEUTICAL INC COM Stock 90400D108 225 -294 -56.65 9 -67.86 0.0002
2024-11-13 2024-09-30 13F ULTRAGENYX PHARMACEUTICAL INC COM Stock 90400D108 519 308 145.97 29 250.00 0.0007
2024-08-08 2024-06-30 13F ULTRAGENYX PHARMACEUTICAL INC COM Stock 90400D108 211 143 210.29 9 166.67 0.0002
2024-05-06 2024-03-31 13F ULTRAGENYX PHARMACEUTICAL INC COM Stock 90400D108 68 37 119.35 3 200.00 0.0001
2024-02-12 2023-12-31 13F ULTRAGENYX PHARMACEUTICAL INC COM Stock 90400D108 31 -238 -88.48 1 -88.89 0.0000
2024-05-20 2023-09-30 13F/A-1 ULTRAGENYX PHARMACEUTICAL INC COM Stock 90400D108 269 -175 -39.41 10 -55.00 0.0003
2023-11-14 2023-09-30 13F ULTRAGENYX PHARMACEUTICAL INC COM Stock 90400D108 269 -175 10 0.0003
2024-05-20 2023-06-30 13F/A-1 ULTRAGENYX PHARMACEUTICAL INC COM Stock 90400D108 444 303 214.89 20 300.00 0.0007
2023-08-04 2023-06-30 13F ULTRAGENYX PHARMACEUTICAL INC COM Stock 90400D108 444 303 20 0.0007
2024-05-20 2023-03-31 13F/A-1 ULTRAGENYX PHARMACEUTICAL INC COM Stock 90400D108 141 -194 -57.91 6 -66.67 0.0002
2023-04-25 2023-03-31 13F ULTRAGENYX PHARMACEUTICAL INC COM Stock 90400D108 141 -194 6 0.0002
2023-02-06 2022-12-31 13F ULTRAGENYX PHARMACEUTICAL INC COM Stock 90400D108 335 221 193.86 16 200.00 0.0007
2022-11-10 2022-09-30 13F ULTRAGENYX PHARMACEUTICAL INC COM Stock 90400D108 114 17 17.53 5 -16.67 0.0002
2022-08-01 2022-06-30 13F ULTRAGENYX PHARMACEUTICAL INC COM Stock 90400D108 97 42 76.36 6 50.00 0.0003
2022-04-28 2022-03-31 13F ULTRAGENYX PHARMACEUTICAL INC COM Stock 90400D108 55 -34 -38.20 4 -42.86 0.0002
2022-01-20 2021-12-31 13F ULTRAGENYX PHARMACEUTICAL INC COM Stock 90400D108 89 84 1,680.00 7 0.0003
2021-11-02 2021-09-30 13F/A-1 ULTRAGENYX PHARMACEUTICAL INC COM Stock 90400D108 5 5 0 0.0000
2021-08-06 2021-06-30 13F ULTRAGENYX PHARMACEUTICAL INC COM Stock 90400D108 0 -7 -100.00 0 -100.00
2021-04-23 2021-03-31 13F ULTRAGENYX PHARMACEUTICAL INC COM Stock 90400D108 7 7 1 0.0000
2019-11-01 2019-09-30 13F ULTRAGENYX PHARMACEUTICAL INC COM Stock 90400D108 0 -28 -100.00 0 -100.00
2019-08-05 2019-06-30 13F ULTRAGENYX PHARMACEUTICAL INC COM Stock 90400D108 28 0 0.00 2 0.00 0.0002
2019-05-01 2019-03-31 13F ULTRAGENYX PHARMACEUTICAL INC COM Stock 90400D108 28 -270 -90.60 2 -83.33 0.0002
2019-02-05 2018-12-31 13F ULTRAGENYX PHARMACEUTICAL INC COM Stock 90400D108 298 252 547.83 12 200.00 0.0017
2018-11-01 2018-09-30 13F ULTRAGENYX PHARMACEUTICAL INC COM Stock 90400D108 46 0 0.00 4 33.33 0.0005
2018-07-30 2018-06-30 13F ULTRAGENYX PHARMACEUTICAL INC COM Stock 90400D108 46 0 0.00 3 50.00 0.0004
2018-05-08 2018-03-31 13F ULTRAGENYX PHARMACEUTICAL INC COM Stock 90400D108 46 0 0.00 2 0.00 0.0003
2018-02-13 2017-12-31 13F ULTRAGENYX PHARMACEUTICAL INC COM Stock 90400D108 46 46 2 0.0003
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.